Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers
Key result
Olpasiran reduces OxPL-apoB by ~94% compared with placebo at 36 weeks.
- MD -93.7%
- 95% CI -107.1 to -80.3
- P<.001
- n=281
Why the study?
Does olpasiran reduce oxidized phospholipids and systemic inflammatory biomarkers in patients with atherosclerotic cardiovascular disease and elevated Lp(a)?
Population
281 patients with atherosclerotic cardiovascular disease and Lp levels greater than 150 nmol/L, median age…
Comparison
Olpasiran administered subcutaneously at 1 of 4… vs Placebo
Design
RCT, randomized, placebo-controlled
Follow-up
48 weeks
Authors
Discussion
Loading...
Member takes
Implication
Olpasiran significantly and sustainably reduces oxidized phospholipids on apolipoprotein B in patients with ASCVD and elevated Lp(a), but does not lower systemic inflammatory markers like hs-CRP or hs-IL-6.
Study Design
Type
RCT (n=281)
Blinding
Placebo-controlled
Randomization
Randomized
Multicenter
Yes
Structured PICO
Does olpasiran reduce oxidized phospholipids and systemic inflammatory biomarkers in patients with atherosclerotic cardiovascular disease and elevated Lp(a)?
P
Population
281 patients with atherosclerotic cardiovascular disease and Lp(a) >150 nmol/L, randomized to olpasiran or placebo and followed for up to 48 weeks.
I
Intervention
Olpasiran administered subcutaneously at 1 of 4 active doses: 10 mg every 12 weeks (Q12W), 75 mg Q12W, 225 mg Q12W, or 225 mg every 24 weeks (Q24W).
C
Comparator
Placebo
O
Outcome
Placebo-adjusted change in OxPL-apoB from baseline to week 36surrogate
Main Result
Mean Difference: -93.7 (95% CI -107.1–-80.3)
p-value: p=<.001
Olpasiran significantly and sustainably reduces oxidized phospholipids on apolipoprotein B in patients with ASCVD and elevated Lp(a), but does not lower systemic inflammatory markers like hs-CRP or hs-IL-6.
Cite This Study
Rosenson et al. (2025) conducted an RCT in Atherosclerotic cardiovascular disease with elevated Lp(a) (n=281). Olpasiran vs. Placebo was evaluated on Placebo-adjusted change in OxPL-apoB from baseline to week 36 (MD -93.7%, 95% CI -107.1 to -80.3, p=<.001). Olpasiran significantly reduced OxPL-apoB at 36 weeks compared with placebo, with a placebo-adjusted mean percentage change of -93.7% (95% CI -107.1 to -80.3; P<.001) for the 225-mg Q24W dose.